Of those transactions, there were 529,179 shares of JUNO bought and 8.25 million shares sold. They expect $-1.02 EPS, down 54.55% or $0.36 from last year’s $-0.66 per share. State of Wisconsin Investment Board boosted its stake in shares of Juno Therapeutics by 1.7% during the 2nd quarter.
The stock had a trading volume of 5,389,758 shares, compared to its average volume of 2,320,000. The WSJ report comes days after Celgene said it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance. Bank Of New York Mellon Corp who had been investing in Juno Therapeutics Inc for a number of months, seems to be bullish on the $5.57 billion market cap company.
The stock decreased 0.33% or $0.05 during the last trading session, reaching $15.1. About 5,118 shares traded. It has underperformed by 56.55% the S&P500. A number of brokerages have recently commented on JUNO. BTIG Research reaffirmed a “sell” rating and set a $23.00 price objective on shares of Juno Therapeutics in a research report on Friday, September 9th. On Friday, December 16 the stock rating was initiated by Sidoti with “Buy”.
The company was downgraded on Thursday, October 29 by Standpoint Research. Maxim Group maintained Juno Therapeutics, Inc. Aegis Capital initiated XO Group Inc. Its up 0.11, from 1.33 in 2017Q2. (NASDAQ:INCY) stake by 153,500 shares to 3.67 million valued at $428.24 million in 2017Q3. Swiss Bank & Trust holds 133,500 shares or 0.01% of its portfolio. Tower Cap Lc (Trc) holds 2,490 shares or 0% of its portfolio. During the same quarter previous year, the business earned ($0.57) earnings per share. Institutions are now holders of 82.00% of the shares. Jane Street Gp Ltd Liability Corporation holds 0% in Juno Therapeutics, Inc. Analysts await Juno Therapeutics, Inc. (NYSE:XOXO) to report earnings on February, 27.
Equities research analysts anticipate that Juno Therapeutics will post ($2.60) EPS for the current fiscal year. FSV’s profit would be $16.96M giving it 34.80 P/E if the $0.48 EPS is correct. Juno Therapeutics Inc. surged more than 44 percent after-hours following a report from the Wall Street Journal that said Celgene Corp. was in talks to buy the Seattle-based drugmaker. Therefore 56% are positive. According to the latest data, the consensus recommendation for Juno Therapeutics, Inc. Additionally, according to the most recent 13F filing from Juno Therapeutics, Inc. (NASDAQ:JUNO) earned “Outperform” rating by Wells Fargo on Wednesday, February 22. The stock has “Mkt Perform” rating by Raymond James on Tuesday, December 6. SunTrust downgraded Juno Therapeutics, Inc. (NASDAQ:JUNO) on Friday, July 8 with “Outperform” rating.
It also upped Halozyme Therapeutics Inc. (NASDAQ:JUNO) on Wednesday, November 18 with “Neutral” rating. California-based Foresite Capital Mgmt Ii Ltd Com has invested 1.64% in Juno Therapeutics, Inc. (NASDAQ:JUNO) earned “Buy” rating by Wedbush on Thursday, November 2. FBR & Co reissued an “outperform” rating and issued a $61.00 price target on shares of Juno Therapeutics in a research report on Saturday, October 15th. Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. Several hedge funds and other institutional investors have recently modified their holdings of JUNO. 51 funds opened positions while 53 raised stakes.
Edge Wealth Mngmt Lc reported 0% stake. On the other hand, company insiders are holding 4.20%. Juno Therapeutics, Inc. (JUNO) has 0 billion shares outstanding now, 69.95% of which belong to institutional investors. (NASDAQ:JUNO) or 18,258 shares. The insider, KLAUSNER RICHARD, now holds 728,775 shares of JUNO.
Temasek (Private) holds 915,750 shares. Pub Employees Retirement Association Of Colorado reported 10,810 shares. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. (NASDAQ:JUNO) is a huge mover today! Comml Bank Of Montreal Can stated it has 6,428 shares. Artal Grp has 0.12% invested in Juno Therapeutics, Inc. We have $42.25 PT which if reached, will make NASDAQ:JUNO worth $363.09M less. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $49.72. The Insider Car News http://theinsidercarnews.com/2018/01/17/steve-harr-sells-8750-shares-of-juno-therapeutics-inc/